Abstract
Intravenous immunoglobulin (IVIG) was initially approved as an alternative to antibodies in the treatment of primary immunodeficiency diseases. With further insights into its action mechanism, IVIG has been successfully applied to the treatment of bullous dermatoses, connective tissue diseases, severe drug eruptions, Kawasaki disease, etc. It has been proved that IVIG has good therapeutic effect and increases the survival of patients. Although IVIG is relatively safe and well tolerable, it has some adverse effects. Currently, lack of large-scale randomized controlled trials (RCTs) remains the biggest problem. Key words: Skin diseases; Immunoglobulins; Injections; Therapeutic uses
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Dermatology and Venereology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
